Social Media Community Guidelines

Revance maintains corporate social media accounts across multiple platforms. We invite you to visit our channels to engage with our content and learn more about our company. By engaging and accessing these accounts, you agree to comply with the rules of engagement. We are committed to facilitating positive engagements and welcome your comments. However, the following are some reasons why we may need to remove or not respond to your comment:

Includes spam, threatening harm to self or others, profanity

Posts that contain derogatory comments, or personal attacks will be removed. Please be respectful and kind and refrain from using vulgar language as any such posts will be removed.

Includes a product complaint, adverse event or side effects

Posts that include comments regarding safety issues, side effects or product complaints. If you experience any medical side effects or reactions, please consult with your healthcare professional immediately. You may report a side effect or adverse event by calling 1-877-3REV-NOW (1-877-373-8669) and select option 1 or emailing RevanceMedInfo@ashfieldhealthcare.com. Alternatively, you can also contact the FDA directly at www.fda.gov/medwatch.com

Includes unapproved products or off-label uses

Posts that include unapproved products or off-label information may be removed. Revance cannot discuss any products that are not approved for use in the U.S. by the Food and Drug Administration or the use of products in any way that is not indicated by the Food and Drug Administration. Please visit www.revance.com for more information on currently approved products and related product information labels. Examples of post which may be removed include:

  • Posts about non- Revance products
  • Posts about unapproved uses of Revance products
  • Posts about Revance products not described in the applicable labeling
  • Post about Revance products in development and not commercially approved

Includes medical advice

Posts that include medical advice to other engaged users. We cannot discuss or provide professional medical advice on an individual’s medical condition. We recommend that all individuals consult with their healthcare professionals on any medical condition.

Thank you for reading and abiding by our community guidelines. We appreciate your interest in Revance and participation within our communities.

IMPORTANT SAFETY INFORMATION for DAXXIFY® (daxibotulinumtoxinA-Ianm) for injection

Indications

(daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients and for the treatment of cervical dystonia in adults.

WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.

IMPORTANT SAFETY INFORMATION

Contraindications

DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).

Warnings and Precautions

Please refer to Boxed Warning for Distant Spread of Toxin Effect.

The potency Units of DAXXIFY® are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.

Adverse Reactions

The most commonly observed adverse reactions are:

Glabellar lines (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%).

Cervical Dystonia (≥5%): headache (9%), injection site pain (8%), injection site erythema (6%), muscular weakness (5%), and upper respiratory tract infection (5%).

Drug Interactions

Co-administration of DAXXIFY® and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY® may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown.

Use in Specific Populations

DAXXIFY® is not recommended for use in children or pregnant women.

Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.

To report side effects associated with DAXXIFY®, please visit safety.revance.com, or call 1-877-373-8669. You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch

DAXI-004726

Facebook Instagram Twitter LinkedIn

FOR CUSTOMER SERVICE, PRODUCT INFORMATION, NEW ACCOUNTS OR ADVERSE EVENTS CALL: 877-3REV-NOW

1222 DEMONBREUN ST

20TH FLOOR

NASHVILLE, TN 37203

©2025 REVANCE.
RHA® and RHA Redensity® are registered trademarks of TEOXANE SA, manufactured in Switzerland. The TEOXANE RHA® Collection is exclusively distributed by Revance®. All other trademarks are the property of their respective owners.
CORP-00147

SOCIAL MEDIA COMMUNITY GUIDELINES PRIVACY POLICY TERMS OF USE
WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.